Atezolizumab bests chemo in NSCLC patients with high PD-L1 expressionNovember 10, 2019Lung CancerImmunotherapy
Levothyroxine dose for checkpoint inhibitor toxicity may be too highNovember 4, 2019MelanomaLung CancerPatient & Survivor CareImmunotherapy
Immunotherapies under investigation in newly diagnosed B-ALLOctober 1, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncology
Adding radiation to immunotherapy may extend PFS in progressive lung cancerSeptember 23, 2019Lung CancerImmunotherapy
CAR T-cell therapy found safe, effective for HIV-associated lymphomaSeptember 20, 2019Lymphoma & Plasma Cell DisordersImmunotherapyDLBCL
Nivolumab falls short in ccRCC patients with brain metastasesAugust 28, 2019Renal Cell CarcinomaImmunotherapyImmuno-oncology
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancerAugust 26, 2019Immuno-oncologyGynecologic CancerImmunotherapy
Lichenoid dermatitis with mycosis fungoides features linked to checkpoint inhibitor therapyJuly 28, 2019ImmunotherapyPatient & Survivor Care
Bullous disorders linked to frequent interruption of immune checkpoint inhibitor treatmentJune 26, 2019Immunotherapy
Novel immune checkpoint holds ‘great promise’ as melanoma treatment targetJune 25, 2019MelanomaImmunotherapy
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019ImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyLeukemia, Myelodysplasia, Transplantation
Checkpoint inhibitor–induced rheumatic complications have unique featuresJune 19, 2019Patient & Survivor CareImmunotherapy
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse eventsJune 14, 2019Immuno-oncologyImmunotherapy
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapiesJune 14, 2019Immuno-oncologyImmunotherapy
